These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 32119801)

  • 21. Clinical implications of the metabolic syndrome.
    Ceska R
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S2-4. PubMed ID: 17935057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of type IIb dyslipidemia.
    Arai H; Ishibashi S; Bujo H; Hayashi T; Yokoyama S; Oikawa S; Kobayashi J; Shirai K; Ota T; Yamashita S; Gotoda T; Harada-Shiba M; Sone H; Eto M; Suzuki H; Yamada N;
    J Atheroscler Thromb; 2012; 19(2):105-14. PubMed ID: 22139432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology.
    Helkin A; Stein JJ; Lin S; Siddiqui S; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2016 Feb; 50(2):107-18. PubMed ID: 26983667
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PCSK9 and resistin at the crossroads of the atherogenic dyslipidemia.
    Rashid S; Kastelein JJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1567-77. PubMed ID: 24134510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome.
    Kumari R; Kumar S; Kant R
    Diabetes Metab Syndr; 2019; 13(4):2409-2417. PubMed ID: 31405652
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
    Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The association between metabolic syndrome components and the development of atherosclerosis.
    Aboonabi A; Meyer RR; Singh I
    J Hum Hypertens; 2019 Dec; 33(12):844-855. PubMed ID: 31636352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Saturated fats and cardiovascular health: Current evidence and controversies.
    Maki KC; Dicklin MR; Kirkpatrick CF
    J Clin Lipidol; 2021; 15(6):765-772. PubMed ID: 34649831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mannose-binding lectin in obesity with different degrees of metabolic syndrome abnormalities: association with atherogenic and metabolic traits.
    Strack C; Baessler A; Wagner F; Bruxmeier J; Yaroslavskii O; Rousseva E; Loew T; Riegger G; Schmitz G; Fischer M
    J Atheroscler Thromb; 2012; 19(6):539-51. PubMed ID: 22472212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathophysiologic mechanisms linking adipose tissue and cardiometabolic risk.
    Allende-Vigo MZ
    Endocr Pract; 2010; 16(4):692-8. PubMed ID: 20439246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.
    Musunuru K
    Lipids; 2010 Oct; 45(10):907-14. PubMed ID: 20524075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management.
    Neeland IJ; Poirier P; Després JP
    Circulation; 2018 Mar; 137(13):1391-1406. PubMed ID: 29581366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: Part I. Increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus.
    Ginsberg HN; MacCallum PR
    J Cardiometab Syndr; 2009; 4(2):113-9. PubMed ID: 19614799
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surrogate markers for atherosclerosis in overweight subjects with atherogenic dyslipidemia: the GEMS project.
    Genoud M; Wietlisbach V; Feihl F; Mermod A; Morin D; Darioli R; Nicod P; Mooser V; Waeber B; Hayoz D; Waeber G
    Angiology; 2008; 59(4):484-92. PubMed ID: 18388087
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasculometabolic and Inflammatory Effects of Aldosterone in Obesity.
    van der Heijden CDCC; Ter Horst R; van den Munckhof ICL; Schraa K; de Graaf J; Joosten LAB; Danser AHJ; Netea MG; Deinum J; Rutten J; Riksen NP
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2719-31. PubMed ID: 32529242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NAFLD and Atherosclerosis: Two Sides of the Same Dysmetabolic Coin?
    Stols-Gonçalves D; Hovingh GK; Nieuwdorp M; Holleboom AG
    Trends Endocrinol Metab; 2019 Dec; 30(12):891-902. PubMed ID: 31630897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective.
    Solnica B; Sniderman AD; Wyszomirski A; Rutkowski M; Chlebus K; Bandosz P; Pencina MJ; Zdrojewski T
    Int J Cardiol; 2023 Nov; 390():131150. PubMed ID: 37429441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.